Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
- PMID: 35490698
- PMCID: PMC7614852
- DOI: 10.1016/S2468-1253(22)00061-9
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
Abstract
Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the general population. The evidence base for the investigation and management of NAFLD is large and growing, but there is currently little practical guidance to support development of services and delivery of care. To address this, we produced a series of evidence-based quality standard recommendations for the management of NAFLD, with the aim of improving patient care. A multidisciplinary group of experts from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group produced the recommendations, which cover: management of people with, or at risk of, NAFLD before the gastroenterology or liver clinic; assessment and investigations in secondary care; and management in secondary care. The quality of evidence for each recommendation was evaluated by the Grading of Recommendation Assessment, Development and Evaluation tool. An anonymous modified Delphi voting process was conducted individually by each member of the group to assess the level of agreement with each statement. Statements were included when agreement was 80% or greater. From the final list of statements, a smaller number of auditable key performance indicators were selected to allow services to benchmark their practice. It is hoped that services will review their practice against our recommendations and key performance indicators and institute service development where needed to improve the care of patients with NAFLD.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests SM personal fees outside the submitted work from Gilead, Intercept, and Novo Nordisk. MJA has received fees for consultancy, advisory boards, and speaking from Novo Nordisk and Norgine. JFC has received fees for consultancy, advisory boards, and speaking from Intercept, Novo Nordisk, canNASH, and AstraZeneca. EAT has received fees for advisory boards and speaking from Falk Pharma, Intercept, Gilead, and Pfizer. AS has received fees for consultancy and speaking from Siemens. STB has received payment for advisory boards and speaking from AbbVie, Gilead, and Intercept. RJA has received honoraria for speaking and advisory board membership from Falk Pharma, Gilead, Intercept, Novartis, and Norgine. DM has received fees for consultancy from Intercept. PNB has received speaking and educational fees from Takeda. RP has received speaking fees and advisory board fees from Siemens, Norgine, Novo Nordisk, and Shionogi. AY has taken part in advisory boards and consultancy for Intercept and Novo Nordisk. HJ has received speaker fees from Intercept. WA has received fees for consultancy and lecturing from AstraZeneca, Janssen, Novo Nordisk, Gilead Science, Intercept, and Coherus and has received competitive grant funding from GSK and Gilead Science. LC has received personal fees outside the submitted work from Norgine, Intercept, and Novo Nordisk. JT has received personal fees outside the submitted work from Novartis and Poxel. QMA is coordinator of the IMI2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. He reports research grant funding from Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Glympse Bio, Novartis Pharma AG, Pfizer Ltd, and Vertex, consultancy on behalf of Newcastle University for 89Bio, Allergan/Tobira, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company, Galmed, Genentech, Genfit, Gilead, Grunthal, HistoIndex, Indalo, Intercept, Inventiva, IQVIA, Janssen, Madrigal, MedImmune, Medpace, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd, Poxel, ProSciento, Raptor Pharma, Roche, Servier, Terns, The Medicines Company, and Viking Therapeutics, and speaker fees from Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, and MedScape. All other authors declared no competing interests.
Figures
Similar articles
-
Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group.BMJ Open Gastroenterol. 2023 Oct;10(1):e001221. doi: 10.1136/bmjgast-2023-001221. BMJ Open Gastroenterol. 2023. PMID: 37797967 Free PMC article.
-
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.World J Gastroenterol. 2014 Sep 14;20(34):12182-201. doi: 10.3748/wjg.v20.i34.12182. World J Gastroenterol. 2014. PMID: 25232252 Free PMC article. Review.
-
National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022.JHEP Rep. 2023 Aug 28;5(12):100897. doi: 10.1016/j.jhepr.2023.100897. eCollection 2023 Dec. JHEP Rep. 2023. PMID: 38023607 Free PMC article.
-
Advancing the global public health agenda for NAFLD: a consensus statement.Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27. Nat Rev Gastroenterol Hepatol. 2022. PMID: 34707258 Review.
-
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.Gastroenterology. 2023 Oct;165(4):1080-1088. doi: 10.1053/j.gastro.2023.06.013. Epub 2023 Aug 4. Gastroenterology. 2023. PMID: 37542503 Review.
Cited by
-
Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.Front Endocrinol (Lausanne). 2022 Nov 3;13:1032164. doi: 10.3389/fendo.2022.1032164. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36407307 Free PMC article.
-
Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.Diabet Med. 2022 Oct;39(10):e14912. doi: 10.1111/dme.14912. Epub 2022 Jul 20. Diabet Med. 2022. PMID: 35790023 Free PMC article. Review.
-
Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.BMJ Open Gastroenterol. 2023 Feb;10(1):e001092. doi: 10.1136/bmjgast-2022-001092. BMJ Open Gastroenterol. 2023. PMID: 36754448 Free PMC article.
-
Multidisciplinary pathway to support lifestyle change: tangible benefits in physical and mental health for patients with nonalcoholic fatty liver disease (NAFLD).Clin Liver Dis (Hoboken). 2023 Mar 1;21(2):60-65. doi: 10.1097/CLD.0000000000000017. eCollection 2023 Feb. Clin Liver Dis (Hoboken). 2023. PMID: 36950305 Free PMC article. No abstract available.
-
Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD.BMJ Open Gastroenterol. 2024 Jul 17;11(1):e001404. doi: 10.1136/bmjgast-2024-001404. BMJ Open Gastroenterol. 2024. PMID: 39019623 Free PMC article.
References
-
- Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672–82. - PubMed
-
- Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ. 2011;343:d3897. - PubMed
-
- Taylor RS, Taylor RJ, Bayliss S, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611–25.:e12. - PubMed
-
- Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical